ENETS expert survey reveals major gaps and disagreements in how to assess response to peptide receptor radionuclide therapy for neuroendocrine tumors.
70% responseENETS Advisory Board survey on PRRT response assessment practices and unmet needs
What the researchers found
Expert survey revealed significant variability and unmet needs in PRRT response assessment, with no consensus on standardized criteria.
Why it matters
Without standardized response criteria, clinicians cannot reliably compare PRRT outcomes across centers or decide when to stop or modify treatment.
The numbers in context
70% of Advisory Board responded; 81% from ENETS Centers of Excellence; 13 questions; 46% achieved >75% agreement; 39% achieved >60% agreement.
How the study worked
Statement-based survey of ENETS Advisory Board members (70% response rate) with 13 questions and substatements.
Who was studied
ENETS Advisory Board members (neuroendocrine tumor specialists)
What this study cannot tell us
Expert survey — reflects opinions rather than evidence. Response criteria have not yet been validated prospectively.
How to read the evidence
Expert consensus survey — captures current practice variability but does not provide validated criteria.
When this study was published
Published in 2025 from the 2022 ENETS meeting, reflecting ongoing efforts to standardize PRRT assessment.
The bigger picture
Standardizing PRRT response assessment would improve clinical trials, enable better comparisons, and ultimately improve patient care.
Questions still open
- Should functional imaging replace morphological criteria for PRRT response?
- Can molecular markers complement imaging for earlier response assessment?
Common questions
How do doctors know if PRRT is working?
Why are standardized criteria important?
Read the original research
Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.
Journal of neuroendocrinology, 37(2), e13479
Citation
Prasad, Vikas; Koumarianou, Anna; Denecke, Timm; Sundin, Anders; Deroose, Christophe M; Pavel, Marianne; Christ, Emanuel; Lamarca, Angela; Caplin, Martyn; Castaño, Justo P; Dromain, Clarisse; Falconi, Massimo; Grozinsky-Glasberg, Simona; Hofland, Johannes; Knigge, Ulrich Peter; Kos-Kudla, Beata; Krishna, Balkundi A; Reed, Nicholas Simon; Scarpa, Aldo; Srirajaskanthan, Rajaventhan; Toumpanakis, Christos; Kjaer, Andreas; Hicks, Rodney J; Ambrosini, Valentina. (2025). Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.. Journal of neuroendocrinology, 37(2), e13479. https://doi.org/10.1111/jne.13479